Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 rearrangements in Anaplastic Large Cell Lymphoma

Aishwarya Ravindran, MBBS, Andrew L. Feldman, MD, Rhett P. Ketterling, MD, Surendra Dasari, PhD, Karen Rech, MD, Ellen D. McPhail, MD, Paul J Kurtin, MD, Min Shi, MDPhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-134547

Published: 2020

Journal Articles

High Level MYC Amplification in Aggressive B-Cell Lymphomas: Is It a Marker of Aggressive Disease?

Priyanka Pophali, MD, Lisa M Marinelli, Rhett P. Ketterling, Reid Gregory Meyer, Ellen D. McPhail, MD, Paul J Kurtin, MD, Thomas M. Habermann, MD, Rebecca L King, MD

Blood (2018) 132 (Supplement 1): 1693.

https://doi.org/10.1182/blood-2018-99-115484

Published: 2018

Journal Articles

An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation

Thomas M. Habermann, MD, Ruth A Lentz, R.N., John J Schmitz, MD, Alexander G von Bormann, BA, Jason Young, MD, Christopher H Hunt, MD, Grzegorz S. Nowakowski, MD, Kristen McCullough, PharmD, Pedro Horna, MD, Adam J Wood, MD, William R. Macon, MD, Paul J Kurtin, MD, Scott L Stafford, MD, Usha Sree Chamarthy, MD, Faraz Khan, MD, Stephen M. Ansell, MD PhD, Rebecca L King, MD

Blood (2018) 132 (Supplement 1): 2247.

https://doi.org/10.1182/blood-2018-99-112887

Published: 2018

Journal Articles

Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements"

Ellen D. McPhail, MD, Matthew J Maurer, MS, Rhett P. Ketterling, MD, William R. Macon, MD, Andrew L Feldman, MD, Paul J Kurtin, MD, Thomas E. Witzig, MD, Rakhee Vaidya, MD, Thomas M. Habermann, MD

Blood (2016) 128 (22): 1750.

https://doi.org/10.1182/blood.V128.22.1750.1750

Published: 2016

Journal Articles

Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas)

Thomas M. Habermann, MD, William R. Macon, MD, Matthew J Maurer, MS, Rhett P. Ketterling, MD, Paul J Kurtin, MD, Andrew L Feldman, MD, Rakhee Vaidya, MD, James R Cerhan, MD PhD, Stephen Ansell, MD PhD, Luis Porrata, MD, Grzegorz S. Nowakowski, MD, Thomas E. Witzig, MD, Ellen D. McPhail, MD

Blood (2016) 128 (22): 155.

https://doi.org/10.1182/blood.V128.22.155.155

Published: 2016

Journal Articles

Immunoglobulin Variable Region Family Usage and Outcomes of Patients with Systemic Light Chain Amyloidosis

Taxiarchis Kourelis, MD, Surendra Dasari, PhD, Paul J Kurtin, MD, Marina Ramirez-Alvarado, PhD, Steven R Zeldenrust, MD PhD, Jason D Theis, BS, Morie A Gertz, MD, Ahmet Dogan, MDPhD, Angela Dispenzieri, MD

Blood (2014) 124 (21): 3402.

https://doi.org/10.1182/blood.V124.21.3402.3402

Published: 2014

Journal Articles

Mass Spectrometry-Based Proteomics Reveals Distinct Immunoglobulin Light Chain Variable Region Usage In Systemic Versus Localized AL Amyloidosis

Oana M Mereuta, M.D., Ph.D., Surendra Dasari, Ph.D, Jason D Theis, BS, Julie A Vrana, Ph.D., Karen L Grogg, M.D., Morie A Gertz, M.D., Steven R. Zeldenrust, M.D., Ph.D., Angela Dispenzieri, MD, Marina Ramirez-Alvarado, Ph.D., Diane F. Jelinek, PhD, Paul J Kurtin, MD, Ahmet Dogan, MD, PhD

Blood (2013) 122 (21): 3142.

https://doi.org/10.1182/blood.V122.21.3142.3142

Published: 2013

Journal Articles

Proteome Of Amyloidosis: Mayo Clinic Experience In 4139 Cases

Jason D Theis, BS, Surendra Dasari, Ph.D, Julie A Vrana, Ph.D., Oana M Mereuta, M.D., Ph.D., Karen L Grogg, M.D., Morie A Gertz, M.D., Steven R Zeldenrust, MD, PhD, Angela Dispenzieri, MD, Paul J Kurtin, MD, Ahmet Dogan, MD, PhD

Blood (2013) 122 (21): 1900.

https://doi.org/10.1182/blood.V122.21.1900.1900

Published: 2013

Journal Articles

IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era

Blood (2013) 122 (21): 362.

https://doi.org/10.1182/blood.V122.21.362.362

Published: 2013

Journal Articles

Del(6)(q22) and BCL6 Rearrangements in Primary Central Nervous System Lymphoma (PCNSL) Are Indicators of an Aggressive Clinical Course.

Francois M. Cady, MD, Mark E. Law, MS, Caterina Giannini, MD, Alyx B. Porter, MD, Brian P. O’Neill, MD, Paul A. Decker, MD, Paul J. Kurtin, MD, Ellen D. Remstein, MD, Ahmet Dogan, MD

Blood (2007) 110 (11): 1557.

https://doi.org/10.1182/blood.V110.11.1557.1557

Published: 2007

Journal Articles

Gene Expression Profiling of Pulmonary Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Identifies New Diagnostic Markers, Biological Heterogeneity and Therapeutic Targets.

Wee J. Chng, MD, Rafael Fonseca, MD, Peter Leif Bergsagel, MD, Julia A. Vrana, Paul J. Kurtin, MD, Ellen Remstein, MD, Ahmet Dogan, MD

Blood (2007) 110 (11): 560.

https://doi.org/10.1182/blood.V110.11.560.560

Published: 2007

Journal Articles

Syk Tyrosine Kinase Is Overexpressed in the Majority of Peripheral T- and NK-Cell Lymphomas, and Represents a Potential Therapeutic Target.

Andrew L. Feldman, MD, David X. Sun, PhD, Mark E. Law, BS, Anne J. Novak, PhD, Ayoma D. Attygalle, MD, Erik C. Thorland, PhD, Stephanie R. Fink, BA, Julie A. Vrana, PhD, B. Lynn Caron, William G. Morice, MD, PhD, Ellen D. Remstein, MD, Karen L. Grogg, MD, Paul J. Kurtin, MD, William R. Macon, MD, Ahmet Dogan, MD, PhD

Blood (2007) 110 (11): 690.

https://doi.org/10.1182/blood.V110.11.690.690

Published: 2007

Journal Articles

Phase II Study of Rituximab and Cladribine (2-CDA) in Newly Diagnosed Mantle Cell Lymphoma (MCL) (N0189).

David James Inwards, MD, David W. Hillman, Paul A. Fishkin, MD, William L. White, MD, Roscoe F. Morton, MD, Shaker R. Dakhil, MD, Daniel A. Nikcevich, MD,PhD, Donald B. Wender, MD, Tom R. Fitch, MD, Paul J. Kurtin, MD

Blood (2006) 108 (11): 2746.

https://doi.org/10.1182/blood.V108.11.2746.2746

Published: 2006

Journal Articles

Ten Year-Old Male with Hemoglobin Lufkin/Beta-Zero Thalassemia Compound Heterozygote Who Exhibited Beta-Thalassemia Major Characteristics.

Ahna M. Blutreich, MD, Peihong Shu, MD, Jeremy S. Bragdon, MD, Paul J. Kurtin, MD, James D. Hoyer, MD, Gungor Karayalcin, MD

Blood (2005) 106 (11): 3815.

https://doi.org/10.1182/blood.V106.11.3815.3815

Published: 2005

NARROW

Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 rearrangements in Anaplastic Large Cell Lymphoma

High Level MYC Amplification in Aggressive B-Cell Lymphomas: Is It a Marker of Aggressive Disease?

An Analysis of a Multidisciplinary Lymphoma Virtual Tumor Board with Regional and International Participation

Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements"

Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas)

Immunoglobulin Variable Region Family Usage and Outcomes of Patients with Systemic Light Chain Amyloidosis

Mass Spectrometry-Based Proteomics Reveals Distinct Immunoglobulin Light Chain Variable Region Usage In Systemic Versus Localized AL Amyloidosis

Proteome Of Amyloidosis: Mayo Clinic Experience In 4139 Cases

IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era

Del(6)(q22) and BCL6 Rearrangements in Primary Central Nervous System Lymphoma (PCNSL) Are Indicators of an Aggressive Clinical Course.

Gene Expression Profiling of Pulmonary Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Identifies New Diagnostic Markers, Biological Heterogeneity and Therapeutic Targets.

Syk Tyrosine Kinase Is Overexpressed in the Majority of Peripheral T- and NK-Cell Lymphomas, and Represents a Potential Therapeutic Target.

Phase II Study of Rituximab and Cladribine (2-CDA) in Newly Diagnosed Mantle Cell Lymphoma (MCL) (N0189).

Ten Year-Old Male with Hemoglobin Lufkin/Beta-Zero Thalassemia Compound Heterozygote Who Exhibited Beta-Thalassemia Major Characteristics.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only